ESTRO meets Asia 2024 - Abstract Book

S145

Interdisciplinary – Gynaecological

ESTRO meets Asia 2024

disease and bilateral parametrial involvement: a phase I-II study. Int J Radiat Oncol Biol Phys 2004, 60(4):1154-1159. 3. Guberina M, Santiago Garcia A, Khouya A, Pottgen C, Holubyev K, Ringbaek TP, Lachmuth M, Alberti Y, Hoffmann C, Hlouschek J et al : Comparison of Online-Onboard Adaptive Intensity-Modulated Radiation Therapy or Volumetric-Modulated Arc Radiotherapy With Image-Guided Radiotherapy for Patients With Gynecologic Tumors in Dependence on Fractionation and the Planning Target Volume Margin. JAMA Netw Open 2023, 6(3):e234066. 4. Wang G, Wang Z, Guo Y, Zhang Y, Qiu J, Hu K, Li J, Yan J, Zhang F: Evaluation of PTV margins with daily iterative online adaptive radiotherapy for postoperative treatment of endometrial and cervical cancer: a prospective single-arm phase 2 study. Radiat Oncol 2024, 19(1):2. 5. Zhang Y, Wang G, Chang Y, Wang Z, Sun X, Sun Y, Zeng Z, Chen Y, Hu K, Qiu J et al : Prospects for daily online adaptive radiotherapy for cervical cancer: Auto-contouring evaluation and dosimetric outcomes. Radiat Oncol 2024, 19(1):6. 6. Bacorro W, Baldivia K, Dumago M, Bojador M, Milo A, Trinidad CM, Mariano J, Gonzalez G, Sy Ortin T: Phase 1/2 trial evaluating the effectiveness and safety of dose-adapted Hypofractionated pelvic radiotherapy for Advanced Cervical cancers INeligible for ChemoTherapy (HYACINCT). Acta Oncol 2022, 61(6):688-697. 7. Wang W, Zhang F, Hu K, Hou X: Image-guided, intensity-modulated radiation therapy in definitive radiotherapy for 1433 patients with cervical cancer. Gynecol Oncol 2018, 151(3):444-448. 8. Duenas-Gonzalez A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H et al : Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011, 29(13):1678-1685. 9. Wagner-Larsen KS, Hodneland E, Fasmer KE, Lura N, Woie K, Bertelsen BI, Salvesen O, Halle MK, Smit N, Krakstad C et al : MRI-based radiomic signatures for pretreatment prognostication in cervical cancer. Cancer Med 2023, 12(20):20251-20265.

214

Digital Poster

Safety and efficacy of Endostar combined with CCRT for LACC: Long-term follow-up

Min Li, Ang Qu, Haitao Sun, Ping Jiang, Junjie Wang

Department of Radiation Oncology, Peking University Third Hospital, Beijing, China

Purpose/Objective:

To evaluate the safety and long-term efficacy of endostar combined with concurrent chemoradiotherapy (CCRT)in patients with locally advanced cervical carcinoma (LACC).

Material/Methods:

A total of 34 patients with LACC were admitted to the Peking University Third Hospital from July 2016 to October 2019.The patients received intravenous infusion of endostar along with CCRT. The study aimed to observe the and long-term efficacy as well as treatment-related side effects in these patients.

Results:

The patients achieved a complete response rate (CRR) of 76.5% and an objective response rate (ORR) of 100%. Median progression-free survival (PFS) and overall survival (OS) have not been determined. At 5 years, the rates